Concord Neonatal, one of the ventures in NLC portfolio, has closed a new funding round, securing substantial funding with private investors. Concord Neonatal is improving birth, by offering solutions to give baby’s a shock-free birth. This new funding allows the company to expand sales internationally and continue to scale-up.
Recent news
Investment in ARNE helps neonatologists treat newborn babies
PRESS RELEASE April 26, 2022 ARNE B.V. has raised financing from Oost NL and venture builder NLC. ARNE supplies smart software with which neonatologists…
Read more
Charles River Laboratories and NLC Collaborate
PRESS RELEASE April 2022 NLC – The European Healthtech Venture Builder and Charles River Laboratories team up to drive drug discovery projects towards finding…
Read more
Scinvivo secures 1 Million investment for in human clinical trials & CE
Press Release Eindhoven, March 10th, 2022 Scinvivo 1 million investment secured towards in human clinical trials & CE for game-changing cancer diagnostics Scinvivo, a…
Read more